Abstract
Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.
Keywords: Endocrine therapy, Endocrine resistance, Estrogen receptor, HER2, AIs, SERMs, SERDs
Anti-Cancer Agents in Medicinal Chemistry
Title:Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Volume: 13 Issue: 3
Author(s): Jinjia Chang and Weimin Fan
Affiliation:
Keywords: Endocrine therapy, Endocrine resistance, Estrogen receptor, HER2, AIs, SERMs, SERDs
Abstract: Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.
Export Options
About this article
Cite this article as:
Chang Jinjia and Fan Weimin, Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/1871520611313030009
DOI https://dx.doi.org/10.2174/1871520611313030009 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry G-Coupled Protein Receptors and Breast Cancer Progression: Potential Drug Targets
Mini-Reviews in Medicinal Chemistry Translation of CYP2D6 Human Genetic Variation into Medical Practice: Lessons Learned and the Way Forward
Current Pharmacogenomics and Personalized Medicine Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Microbiota Regulation of Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Validation of Human Clinical Genetic Tests
Mini-Reviews in Medicinal Chemistry Actual and Potential Agents and Biomarkers in the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry New Approach to Cancer Therapy: The Application of Signal Transduction to Anti-Cancer Drug
Current Medicinal Chemistry - Anti-Cancer Agents Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Cell Adhesion Molecules and Cadmium
Current Chemical Biology